Den europeiske union - norsk - EMA (European Medicines Agency)

ultragenyx germany gmbh - evinacumab - hyperkolesterolemi - lipid modifiserende midler - evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (ldl-c) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (hofh).

Norge - norsk - Statens legemiddelverk

2care4 aps - aminosyrer, uspesifisert / glukose / fettemulsjon / elektrolytter - infusjonsvæske, emulsjon

Den europeiske union - norsk - EMA (European Medicines Agency)

stemline therapeutics b.v. - selinexor - multippelt myelom - antineoplastiske midler - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Den europeiske union - norsk - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, type 2 - legemidler som brukes i diabetes - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgjengelige data på forskjellige kombinasjoner).

Norge - norsk - Statens legemiddelverk

accord healthcare b.v. - vildagliptin - tablett - 50 mg

Norge - norsk - Statens legemiddelverk

krka, d.d. novo mesto - vildagliptin - tablett - 50 mg

Norge - norsk - Statens legemiddelverk

krka, d.d. novo mesto - vildagliptin / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 1000 mg

Norge - norsk - Statens legemiddelverk

krka, d.d. novo mesto - vildagliptin / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 850 mg

Norge - norsk - Ecolab

ecolab deutschland gmbh -

Den europeiske union - norsk - EMA (European Medicines Agency)

takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - antineoplastiske midler - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.